OrbiMed
About OrbiMed
From biopharmaceuticals to medical devices, diagnostics, and healthcare services, OrbiMed is scouting the globe for innovations that will help ensure humanity lives healthier, longer and more productive lives. We have been investing globally for over 20 years across the healthcare industry: from early-stage private companies to large multinational corporations. Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $14 billion across public and private company investments worldwide.
Recent News
Terremoto Wins $108m in Series C to Drive Cancer and Rare Disease Programmes
Aspen Neuroscience Lands $115M Series C
Pinnacle Medicines Adds $89M for Oral Peptides With Properties of Injectable Biologics
Mendra Raises $82M in Series A Funding
Syneron Raises $150m for Macrocyclics, and Other Financings
How to Invest in Healthcare's Powerful Growth
SpectronRx Raises $85 Million to Expand Isotope Production and Manufacturing Capacity
Amid Ownership Transition, Sirona’s Revenue Drops to Rs 77 Cr in FY25
Argenx Names New CEO; Van Hauwermeiren to Become Chair
Radiopharma Firm Secures $85M to Expand Domestic Production of Radioisotopes
Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics
Terremoto Raises $108M to Pursue Development of Drugs Targeting AKT
Adcendo Raises $75M to Advance Cancer Drug Pipeline
BlossomHill Therapeutics Inks $84M Series B Extension
Sidewinder Targets Solid Tumors with Bispecific ADCs on Novartis-Backed Funding
Regional VC Activity Holds Steady Amid Middle‑East Conflict, Highlighting $280M Indian Unicorn Deal
Recent Deals
Aspen Neuroscience Secures $115M Series C Funding
Venture Catalysts Exits Pee Safe in $32M OrbiMed-Led Minority Recap
BlossomHill Therapeutics Secures $84M Series B Extension Funding
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Mendra Therapeutics Raises $82M Series A to Accelerate Rare Disease Drug Development
AirStrip Secures $50M Growth Credit Commitment From OrbiMed, Plus Additional Preferred Stock Investment
Immunic Raises up to $400M in Oversubscribed Private Placement
Congruence Therapeutics Raises $39.5M in Financing Round Led by Dimension and OrbiMed
Biobeat Raises $50M in Series B Funding
Terremoto Biosciences Raises $108M in Series C Financing Round
SpectronRx Raises $85M From OrbiMed to Expand Isotope Production
BlossomHill Therapeutics Secures $84M Series B Extension
